MyFinsight
Home
Blog
About
Proceeds from issuance of
preferred stock and common...
$241K
Proceeds from issuance of
common stock, net of...
$69K
Net cash provided by
financing activities
$231K
Canceled cashflow
$79K
Net decrease in cash
and cash...
-$5,107K
Canceled cashflow
$231K
Offering costs in advance
of sale of common...
$76K
Proceeds from warrant
exercises, net of fees
-$3K
Net cash used in
operating activities
-$5,281K
Net cash used in
investing activities
-$57K
Amortization of debt discount
and debt issuance...
$489K
Depreciation
$358K
Accrued expenses
$341K
Amortization of right-of-use
asset
$251K
Non-cash interest
expense
$203K
Prepaid expenses and
other current assets
-$163K
Stock-based compensation
$133K
Accounts payable
$10K
Net cash used in
operating activities -...
-$5,274K
Net cash provided by
(used in) operating...
-$7K
Canceled cashflow
$1,948K
Acquisition of property and
equipment
$57K
Net loss from
continuing operations
-$7,057K
Lease liabilities
-$114K
Change in fair value of
derivative liability
$47K
Other assets
$4K
Back
Back
Cash Flow
Valion Bio, Inc. (VBIO)
Valion Bio, Inc. (VBIO)
source: myfinsight.com